Healio Minute

In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have 'best shot' at remission for double refractory CLL; mortality factors among cancer survivors and more. Read the full coverage here:

FDA approves Vanflyta for newly diagnosed acute myeloid leukemia

VIDEO: Liso-cel could have 'best shot' at remission for double refractory CLL

Community affluence, insurance mediate CV mortality among Black, white cancer survivors

VIDEO: MOLTO study probes combination therapy in Richter syndrome

Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome

References:

ASCO Annual Meeting ASCO Annual Meeting Press Release Press Release Sung H, et al. Int J Epidemiol. 2023;doi:10.1093/ije/dyad097.

In this edition, lack of sunless tanner education may cause confusion; intralesional HPV vaccine may clear recalcitrant warts; Ilumetri improves well-being of patients with plaque psoriasis and more. Read the full coverage here:

Lack of sunless tanner education may cause diagnostic confusion, UV exposure

Intralesional HPV vaccine may clear recalcitrant warts

New, positive results show Ilumetri improves well-being of patients with plaque psoriasis

AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis

TikTok 'excellent opportunity' for dermatologists to create skin of color content

References:

Campbell JR, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7061. Hatch J, et al. Poster. Sunless tanners: An analysis of most common ingredients. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans. Nofal A, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.06.042. Press Release Spelman L, et al. Phase 2 trial of novel topical drug candidate AB-101a for treatment of mild to moderate atopic dermatitis in children and adults. Presented at: 25th World Congress of Dermatology; July 3-8, 2023; Singapore.

In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more. Read the full coverage here:

Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia

Pirtobrutinib produces high response rates in heavily pretreated CLL, SLL

CDC study reveals overall increase in pediatric cancer incidence over 16 years

Cancers with high incidence among racial/ethnic minorities receive less research funding

Women more likely to experience severe toxicity from cancer treatment

References:

Haghighat S, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad097.

Mato AR, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2300696.

Shimony S, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2023009976.

Siegel DA, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad115.

Unger JM, et al. Abstract SY43-03. Presented at American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando.

In this edition, novel serum improves hair growth in androgenetic alopecia; cardiovascular disease linked to dermatological inflammatory diseases; sugary drinks may be associated with male pattern hair loss and more. Read the full coverage here:

Novel serum improves hair growth in androgenetic alopecia with no side effects

Cardiovascular disease associated with four dermatological inflammatory diseases

Consumption of sugary drinks may be associated with male pattern hair loss

Researchers advocate for promotion of skin self-examination for early melanoma detection

Plaque psoriasis oral therapy moves to phase 3 trial, being tested in other conditions

References:

Ingrassia JP, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.05.098.

Pagan AD, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7424. Press Release Rapaport J, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7403. Shi X, et al. Nutrients. 2023;doi:10.3390/nu15010214.

In this edition, CAR-T trial for leukemia paused after patient death; obesity may increase risk for blood cancer; new CAR T-cell therapies 'waiting' for patients with leukemia and more. Read the full coverage here:

Seattle Children's pauses trial of CAR-T for leukemia after patient death

Obesity may increase risk for blood cancer

VIDEO: New CAR T-cell therapies 'waiting in the wings' for patients with leukemia

VIDEO: Jaktinib shows promise in treatment of myelofibrosis

Venetoclax regimen not superior to standard therapy alone for older patients with CLL

References:

ASCO Annual Meeting

ASCO Annual Meeting Pasupuleti SK, et al. J Clin Invest. 2023;doi:10.1172/JCI163968. Press Release Woyach JA, et al. Abstract 7500. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023; Chicago.

In this edition, Leqembi shows benefits in early Alzheimer's, sex before bed has more positive impact on sleep, clearer guidelines needed on melatonin use in children and more.

Read the full coverage here:

FDA committee says Leqembi shows benefits in early Alzheimer's

Sex before bed has more positive impact on sleep vs. medication in adults with insomnia

Increased education, clearer guidelines needed on melatonin use in children

FDA approves Elevidys for pediatric Duchenne muscular dystrophy

CMS announces plan for Medicare coverage of approved Alzheimer's drugs

References:

Kirsch D, et al. How well does sexual activity improve sleep when compared with pharmacologic sleep aids? Presented at: SLEEP; June 3-7, 2023; Indianapolis.

Owens J. Navigating the challenges in talking to patients and families about melatonin. Presented at: SLEEP; June 3-7, 2023; Indianapolis.

Press Release

Press Release

Press Release

In this edition, prior authorization linked delay in prescription fills; disparities in access to specialized cancer centers; 'new potential treatment option' for advanced chronic lymphocytic leukemia and more. Read the full coverage here:

Prior authorization policies linked to 2-week delay in anticancer-drug prescription fills

AYAs with rare leukemia face disparities in access to specialized cancer centers

Liso-cel CAR-T 'new potential treatment option' for advanced chronic lymphocytic leukemia

Benefits of ivosidenib regimen for IDH1-mutant AML increase with longer follow-up

Childhood cancer survivors at increased risk for sleep concerns decades after diagnosis

References:

Daniel LC. Sleep in long-term childhood cancer survivors compared to siblings: A report from the Childhood Cancer Survivor Study. Presented at: SLEEP; June 3-7, 2023; Indianapolis.

De Botton S, et al. Abstract 7012. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Kyle MA, et al. Abstract 1504. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Muffly L, et al. Abstract 7008. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Siddiqi T, et al. Abstract 7501. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more.

Read the full coverage here:

Surgery confers higher 5-year survival rates than radiotherapy in early-stage lung cancer

First-line combination extends PFS in lung cancer subgroup

Pembrolizumab improves outcomes in early-stage resectable lung cancer

Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC

Severe myelosuppression common after chemotherapy for small cell lung cancer

References:

Hart L, et al. Cancer Med. 2023;doi:10.1002/cam4.5738.

Kanda S, et al. Abstract LBA9009. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Press Release

Udelsman B, et al. Abstract 275. Presented at: American Association for Thoracic Surgery Annual Meeting; May 6-9, 2023; Los Angeles.

Wakelee H, et al. Abstract LBA100. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

In this edition, cross-border partnership takes on survival gap for children with leukemia; 'paradigm shift' in transfusion-dependent myelodysplastic syndrome; FDA approves Ayvakit for mastocytosis and more. Read the full coverage here:

Cross-border partnership takes on 'huge survival gap' among children with leukemia

Luspatercept 'a paradigm shift' in transfusion-dependent myelodysplastic syndrome

FDA approves Ayvakit for indolent systemic mastocytosis

Novel leukemia treatment signals 'new era in CAR T-cell therapy'

Functional precision medicine-guided approach benefits pediatric patients with cancer

References:

Acanda de la Rocha AM, et al. Abstract LB358. Presented at: American Association of Cancer Research Annual Meeting; April 14-19, 2023; Orlando.

Appelbaum J, et al. Abstract 3092. Presented at: American Society of Gene & Cell Therapy Annual Meeting; May 16-20, 2023; Los Angeles.

Aristizabal P, et al. Abstract 1502. Presented at: ASCO Annual Meeting; June 2-6, 2022; Chicago.

Garcia-Manero G, et al. Abstract 7003. Scheduled for presentation at: ASCO Annual Meeting; June 2-6, 2022; Chicago.

Press Release

In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer's and more.

Read the full coverage here:

FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation

Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment

Leqembi reduced biomarkers of Alzheimer's, slowed cognitive decline at 18 months

FDA grants 510(k) clearance for self-directed EEG headset

Oral Bruton's tyrosine kinase inhibitor reduced brain lesions in phase 2 MS trial

References:

Altomare D, et al. JAMA Neurol. 2023;doi:10.1001/jamaneurol.2023.0997.

Press Release

Press Release

Press Release

Van Dyck CH, et al. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer's disease (Clarity AD). Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.